ALK and non-small cell lung carcinoma: Moreover, the NCCN-NSCLC panel has deleted the option to continue crizotinib in patients with BM who had progressed after first-line therapy with crizotinib, suggesting the use of the other ALK inhibitors in this setting, as indicated in NCCN guidelines [31].